From: Effectiveness and safety of KunXian capsule for the treatment of IgA nephropathy
Factor a | Complete or Partial remission | Complete remission | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P value | HR | 95% CI | P value | |
Sex (Female) | 3.67 | 1.63–8.27 | 0.001 | 3.62 | 1.39–9.42 | 0.008 |
Age at baseline (For every 10 years old) | 0.98 | 0.93–1.03 | 0.41 | 1.01 | 0.95–1.07 | 0.68 |
Proteinuria at baseline (g/24 h) b | 0.17 | 0.04–0.85 | 0.03 | 0.02 | 0.002–0.29 | 0.003 |
eGFR at baseline (For every 10 ml/min per 1.73 m2) | 0.92 | 0.66–1.29 | 0.64 | 1.49 | 0.88–2.55 | 0.14 |
Mean artery pressure at baseline (For every 10 mmHg) | 1.03 | 0.97–1.55 | 0.88 | 0.85 | 0.49–1.48 | 0.57 |
Switching from TW | 0.22 | 0.08–0.55 | 0.001 | 0.15 | 0.04–0.57 | 0.005 |
KX Dosage (For every 20μg per capsule) | 1.33 | 0.93–1.91 | 0.12 | 2.62 | 1.47–4.69 | 0.001 |